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Loss to follow-up is an endemic feature of time-to-event analyses that precludes observation of the event of inter-
est. To our knowledge, in typical cohort studies with encounters occurring at regular or irregular intervals, there is
no consensus on how to handle person-time between participants’ last study encounter and the point at which they
meet a definition of loss to follow-up. We demonstrate, using simulation and an example, that when the event of
interest is captured outside of a study encounter (e.g., in a registry), person-time should be censored when the
study-defined criterion for loss to follow-up is met (e.g., 1 year after last encounter), rather than at the last study
encounter. Conversely, when the event of interest must be measured within the context of a study encounter (e.g.,
a biomarker value), person-time should be censored at the last study encounter. An inappropriate censoring
scheme has the potential to result in substantial bias that may not be easily corrected.
bias (epidemiology); censoring; epidemiologic methods; loss to follow-up; selection bias; survival analysis
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; CI, confidence interval; HIV, human
immunodeficiency virus; IDU, injection drug use; IDUs, injection drug users; IPCWs, inverse probability of censoring weights; IQR,
interquartile range; LTFU, lost to follow-up; PWID, persons who inject drugs.
Censoring is an endemic feature of time-to-event analysis
that precludes observation of the event. Right-censoring oc-
curs when an event may have occurred after the last time a per-
son was under observation, but the specific timing of the event
is unknown. Right-censoring may occur at the end of the study
period (i.e., administrative censoring) or when a person fails to
return for a study visit (i.e., is lost to follow-up (LTFU)). In
contrast to administrative censoring, which coincides with the
end of the analytical period and can be placed precisely in
time, LTFU is a nonevent. As such, there is a lack of consensus
on when exactly a study participant becomes “lost” and how to
treat person-time analytically for participants who are LTFU.
Specifically, if LTFU is defined as 12 months without a clinic
encounter, should the censoring date be the date of the last
encounter or the date on which the definition of LTFU is met?
Despite the near ubiquity of LTFU, to our knowledge, the im-
plications of alternative approaches for dealing with person-
time between the last encounter and the time point at which the
definition of LTFU is met have not been formally examined.
Herein, we discuss characteristics of the study design and
research question that may influence the censoring scheme.
Specifically, we make the case that the least biased censoring
scheme depends on whether the outcome is detected outside
of or within a study encounter. We demonstrate bias that may
result from an inappropriate LTFU censoring strategy with a
simulation and a simple example.
CONCEPTUAL FRAME
As we demonstrate in the subsequent simulation, the most
appropriate censoring strategy depends on the nature of the out-
come of interest. For the purposes of this paper, we dichotomize
outcomes into 2 types: those that are captured and those that are
measured. We are not aware of existing, commonly accepted
terms that encapsulate this distinction, and we define our usage
of these terms as follows. We classify outcomes as captured if
they are detectable outside of a study visit (e.g., death, hospital
admission, cancer diagnosis reported to a registry). We classify
outcomes asmeasured if they are only detectable within a study
visit (e.g., change in a biomarker requiring a laboratory test,
remission of depressive symptoms reportable on a standardized
survey). Classification of outcomes as captured or measured
will depend on the study design and setting. For example, we
cite cancer diagnosis as an example of a captured outcome
because in the United States, there are population-based cancer
registries in almost all states. However, in other settings, can-
cer registries may be imperfect or nonexistent and cancer diag-
nosis might be classified as a measured outcome if it would
only be detectable when reported at a study visit.
Herein, we explore 2 possible censoring schemes that repre-
sent the most common analytical approaches for addressing
LTFU. Using (what we dub) “last-encounter” censoring, parti-
cipants who are LTFU are censored at their last study encoun-
ter. Using “LTFU-definition” censoring, participants who are
LTFU are censored when theymeet the definition of LTFU.
METHODS
To illustrate how the date of the last study visit, the point at
which the definition of LTFU ismet, and the censoring scheme
interact to determine the period inwhich participants aremethod-
ologically “at risk” for the outcome, we generated 2 figures with
several illustrative person-records and their treatment under
each of the 2 censoring schemes. Figure 1 assumes a captured
outcome and Figure 2 assumes a measured outcome. In both
cases, LTFU was defined as 12 months with no study visits.
To increase the applicability of our results, we chose to depict
2 main cohort study designs: an interval cohort study in Fig-
ure 1 and a clinical cohort study in Figure 2 (1).
Simulation
Full details of the simulation are provided in Web Appen-
dix 1 (available at https://academic.oup.com/aje). Briefly, we
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Figure 1. Several illustrative study records for hypothetical individuals
(numbered) in an interval cohort study under 2 different censoring
schemes (last-encounter censoring, denoted A, and lost-to-follow-up
(LTFU)-definition censoring, denoted B). Study visits are represented by
stars. The outcome is captured (e.g., in a registry) outside of a study visit,
and its occurrence is denoted by a circle. Outcomes included in the anal-
ysis are denoted by solid circles, while outcomes excluded from analysis
(because they occur after the LTFU definition is met) are denoted by hol-
low circles. LTFU is defined as going 12 months without a study visit or
occurrence of the outcome. For persons who are administratively cen-
sored (e.g., participant 4) or LTFU (e.g., participants 1 and 2), person-time
could be included from study entry to the last study visit (last-encounter
censoring) or from study entry to the point at which the definition of
LTFU is met or to administrative censoring (LTFU-definition censoring).
Included person-time under each censoring scheme is denoted by gray
shaded rectangles. Note that application of last-encounter censoring
results in complete exclusion of persons who never return for a follow-
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Figure 2. Several illustrative study records for hypothetical indivi-
duals (numbered) in a clinical cohort study under 2 different censoring
schemes (last-encounter censoring, denoted A, and lost-to-follow-up
(LTFU)-definition censoring, denoted B). Study visits are represented
by stars. A 5-pointed star indicates a visit at which the outcome has not
yet occurred; a starburst indicates a visit at which the outcome is de-
tected. The outcome is measured; its timing is unobserved, and its
occurrence is denoted by a hollow circle. For persons whose outcome
is observed (e.g., participant 4), person-time is included from study
entry to the visit at which the outcome occurs. (Although the occurrence
of the outcome could be thought of as interval-censored, interval cen-
soring is rarely employed; see Web Appendix 2.) LTFU is defined as
going 12 months without a study visit. For persons who are administra-
tively censored (e.g., participant 5) or LTFU (e.g., participants 1–3),
person-time could be included from study entry to the last study visit
(last-encounter censoring) or from study entry to the point at which the
definition of LTFU ismet or to administrative censoring (LTFU-definition
censoring). Included person-time under each censoring scheme is
denoted by gray shaded rectangles. Note that application of last-
encounter censoring results in complete exclusion of persons who
never return for a follow-up visit (e.g., participant 2). Further note
that, because the outcome is not observable outside of the context
of a study visit, the outcome for individual 3 is unobserved and is not
included in the analysis, despite its occurrence during person-time
included under LTFU-definition censoring.
we simulated a visit schedule such that visits occurred at irregu-
lar intervals approximately everyMmonths. Next we assigned
binary baseline exposure A and binary time-varying exposure Xj
(which changed at most once from 0 to 1, in a month correspond-
ing to a visit), where j indexed month of follow-up. We explored
bias for a time-fixed exposure (A) versus time-varying exposure
(Xj) in separate analyses. The outcomeY could occur in anymonth
and was a function of A and Xj. The cumulative incidence of Y
due toA and the cumulative incidence of Y due to X (simulated
truth) are illustrated inWeb Figures 1 and 2, respectively.
For captured outcomes, we assigned event time T equal to
the month J in which Y occurred. For measured outcomes,
we assigned event time T equal to the next clinic visit jk+1,
where k indexes visits. The measured event is therefore, in
actuality, interval-censored, although most analyses do not
treat measured events as interval-censored. We explore this
issue more in Web Appendix 2; results of analyses treating
measured events as if they were interval-censored appear in
Web Table 1.
We estimated the bias of last-encounter censoring and
LTFU-definition censoring under several scenarios. In each
scenario, we simulated random variableD (months of follow-
up) and assigned observations a last visit L = max(JK ≤ D).
We simulatedD for each scenario as follows:
1. D is random.
2. D is associated with A.
3. D is associated with Xj.
between history of injection drug use (IDU) as a risk factor for
acquisition of human immunodeficiency virus (HIV) and time
from clinic enrollment to 1) initiation of antiretroviral therapy
(ART) (a measured outcome) and 2) death (a captured outcome)
in the Johns Hopkins HIV Clinical Cohort. The Johns Hopkins
HIV Clinical Cohort includes data on all adults receiving conti-
nuity care at the Moore Clinic for HIV Care (Baltimore, Mary-
land) who have agreed to share their data (>90%).We followed
ART-naive patients from enrollment at the clinic between Janu-
ary 1, 1998, and August 30, 2015, to 1) ART initiation, death,
LTFU (12months without a CD4 cell count, viral loadmeasure-
ment, or clinic visit), or administrative censoring (at 5 years or
on August 31, 2015) and to 2) death, LTFU, or administrative
censoring, whichever came first. ART initiation was defined
as initiation of ≥3 antiretroviral medications on 1 day. Deaths
were ascertained through matches against the Social Secu-
rity Death Index.
When analyzing time to ART initiation, we treated patients
who died (a competing event) prior to ART initiation as LTFU
(censored them). We acknowledge that best practice is to not
conflate competing events and LTFU (2), but for the purposes
of illustration we will ignore the question of competing risks
until we reach the Discussion section.
To account for differences in patient characteristics at base-
line among persons who inject drugs (PWID) and non–injection
drug users (non-IDUs), we estimated inverse probability of ex-
posure weights (3, 4) conditional on sex, black race, prior
acquired immunodeficiency syndrome (AIDS) diagnosis or
exposure to mono- or dual ART, and baseline age, CD4 cell
count, and log10 viral load (measurement most proximal to
clinic enrollment, drawn up to 12 months prior). To account
for possibly nondifferential LTFU, we used IPCWs (5) condi-
tional on baseline covariates and time-varying AIDS diagno-
sis, most recent CD4 cell count, and log10 viral load, months
since baseline, and IDU (exposure). We modeled continuous
variables using a restricted quadratic spline (6). This example
is similar to the analysis of HIV-infected women described by
Buchanan et al. (7).
We applied last-encounter censoring and LTFU-definition
censoring in separate analyses. We estimated hazard ratios
using an inverse-probability-weighted Cox proportional haz-
ards model (8), and we estimated the conditional 5-year risk
for PWID and non-IDUs and the 5-year risk difference and
risk ratio based on the complement of inverse-probability-
weighted survival curves (9, 10). We report 95% confidence
intervals based on the 2.5th and 97.5th percentiles of the dis-
tribution of estimates from 1,000 nonparametric bootstrap re-
samples of the data (11).
RESULTS
Figures 1 and 2 depict several person-records and their
treatment under each censoring scheme. The most illustrative
person in both figures is participant 3, who has her last study
visit in month 5 of follow-up and experiences an event in
month 8. When the event is captured (Figure 1), participant 3
is observed to experience the event, precluding her meeting
the definition of LTFU; thus, under both censoring schemes,
the amounts of person-time she contributed are equivalent.
We defined LTFU as 12 months without a study visit, such that 
the definition of LTFU was met at L + 12. The average proba-
bility of LTFU under each scenario above is reported in Web 
Table 2. Captured outcomes were included (i.e., the LTFU defi-
nition was not met because it was precluded by an event) and
the end of follow-up was set to T if T ≤ L + 12; if T > L + 12, 
outcomes were excluded (all person-time and events after L + 
12 were censored). Measured outcomes were included and the
end of follow-up was set to T if T ≤ L; if T > L, outcomes were 
excluded. We set the end of follow-up to L under last-encounter 
censoring and to L + 12 under LTFU-definition censoring.
We estimated the 10-year risk, risk difference, risk ratio, 
and hazard ratio for the effect of A on Y and X̄ on Y in each 
simulation. Here X̄ denotes history of treatment, set to always 
(Xj = 1 for  all j) or never (Xj = 0 for all j). For scenarios in 
which censoring was associated with A or Xj, we estimated  
inverse probability of censoring weights (IPCWs) (assuming 
the censoring mechanism was known) and calculated weighted 
estimates of the 10-year risk, risk difference, risk ratio, and haz-
ard ratio. We estimated average bias as β̂ − β and percent bias
as average bias/β × 100. We also report the median values and 
interquartile ranges of biases (β̂ − β). We do not report the var-
iance or mean squared error because we used the same estima-
tors with both censoring schemes, and thus variances were 
similar across simulations and all differences in mean squared 
error were driven by bias.
Example
To show the impact of different censoring schemes on param-
eter estimates in real-world data, we report the association
However, had participant 3 not had an event, she would have
looked like participant 1, who met the definition of LTFU at
17 months. Under LTFU-definition censoring, we still include
the person-time after participant 1’s last visit, but under last-
encounter censoring, person-time from month 5 onward is
excluded. This differential treatment of person-time for partici-
pants who have and do not have an event under last-encounter
censoring can lead to bias when studying captured outcomes.
When the outcome is measured (Figure 2), the fact that par-
ticipant 3 does not return after month 5 means we would not
observe her event in month 8. However, under LTFU-definition
censoring, we include person-time from month 5 to month 17,
despite not being able to observe an event even if it had occurred,
making this person-time functionally immune. Thus, in contrast
to captured outcomes, when analyzing time to a measured out-
come, participants whomeet the definition of LTFU should be
censored at their last visit.
Simulation
The true risks for a captured or measured outcomewere simi-
lar in our simulated data set. For a captured outcome, 10-year
risk was 52.4% and 31.3%, respectively, for persons assigned
A = 1 and A = 0; the risk difference was 21.1%, the risk ratio
was 1.68, and the hazard ratio was 1.99. When censoring was
random (and 66.8% of persons were LTFU; Web Table 2),
LTFU-definition censoring resulted in percent bias ≤1% for
all estimands (Table 1). However, last-encounter censoring re-
sulted in risk functions that were biased upwards: Percent bias
in 10-year risk under A = 1 and A = 0 was 11.9% and 16.1%,
respectively. Some bias canceled out, such that percent bias
in the risk difference, risk ratio, and hazard ratio was 5.7%,
−6.8%, and −1.0%, respectively. Figure 3 shows the esti-
mated cumulative incidence of Y for persons with A = 1 under
no censoring, LTFU-definition censoring, and last-encounter
censoring. A similar pattern (negligible to no bias under LTFU-
definition censoring and substantial upward bias of risk under
last-encounter censoring) was seen when LTFU was faster for
persons with A = 1.When LTFUwas more likely when Xj = 1,
both censoring schemes produced bias, although again bias was
stronger under last-encounter censoring. IPCWs mitigated the
bias under LTFU-definition censoring but failed to remove the
bias under last-encounter censoring (Web Table 3).
For ameasured outcome and random LTFU, last-encounter
censoring resulted in minimal upward bias of risk estimates.
Percent bias in 10-year risk under A = 1 and A = 0 was 2.4%
and 3.4%, respectively (Table 2). Percent bias in the risk dif-
ference, risk ratio, and hazard ratio was 0.9%, −1.3%, and
Table 1. Bias in the Estimated Effects of a Baseline Exposure on a CapturedOutcome (e.g., Death) in the Presence of Loss to Follow-Up (LTFU)
When Person-Time for Those Lost Is Censored at the Time of the Last Encounter or the Point AtWhich the Definition of LTFU IsMeta
Estimand Truth
Last-Encounter Censoring LTFU-Definition Censoring
Estimate Biasb %Bias Median Bias (IQR) Estimate Biasb %Bias Median Bias (IQR)
LTFU is Random
Risk
A = 1 52.4 58.6 6.2 11.9 5.0 (3.2 to 6.8) 52.3 −0.2 −0.3 0.0 (−1.6 to 1.6)
A = 0 31.3 36.3 5.0 16.1 6.3 (4.4 to 8.0) 31.3 0.1 0.2 −0.2 (−2.0 to 1.5)
RD 21.1 22.3 1.2 5.7 1.2 (−1.4 to 3.8) 20.9 −0.2 −1.1 −0.2 (−2.7 to 2.3)
RR 1.68 1.62 −0.035 −6.8 −0.038 (−0.094 to 0.026) 1.68 −0.003 −0.6 −0.008 (−0.067 to 0.061)
HR 1.99 1.97 −0.007 −1.0 −0.006 (−0.070 to 0.058) 1.98 −0.002 −0.4 −0.003 (−0.068 to 0.063)
LTFUOccurs at a Faster RateWhen A = 1
Risk
A = 1 52.4 60.2 7.8 14.8 4.2 (2.6 to 5.7) 52.5 0.1 0.1 0.0 (−1.5 to 1.4)
A = 0 31.3 35.4 4.2 13.3 7.8 (5.7 to 9.8) 31.2 −0.1 −0.2 0.1 (−2.0 to 2.1)
RD 21.1 24.8 3.6 17.1 3.5 (0.9 to 6.3) 21.3 0.1 0.6 0.0 (−2.4 to 2.7)
RR 1.68 1.71 0.014 2.8 0.013 (−0.043 to 0.068) 1.69 0.004 0.8 0.005 (−0.060 to 0.062)
HR 1.99 2.11 0.061 9.0 0.057 (0.000 to 0.126) 1.99 0.004 0.6 0.002 (−0.057 to 0.068)
LTFU is More LikelyWhen Xj = 1
Risk
A = 1 52.4 59.1 6.7 12.8 5.0 (3.4 to 6.6) 53.5 1.1 2.1 0.6 (−0.7 to 2.1)
A = 0 31.3 36.3 5.0 16.1 6.7 (4.8 to 8.5) 32.0 0.7 2.2 1.1 (−0.7 to 2.9)
RD 21.1 22.8 1.7 7.9 1.7 (−0.6 to 4.1) 21.5 0.4 1.9 0.4 (−1.8 to 2.6)
RR 1.68 1.64 −0.028 −5.3 −0.029 (−0.077 to 0.026) 1.68 0.000 −0.1 −0.001 (−0.052 to 0.053)
HR 1.99 1.98 0.001 0.2 0.002 (−0.059 to 0.062) 1.99 0.004 0.6 0.007 (−0.055 to 0.065)
Abbreviations: HR, hazard ratio; IQR, interquartile range; LTFU, lost to follow-up; RD, risk difference; RR, risk ratio.
a Full details of the simulations are provided inWeb Appendix 1.
b Absolute bias is on the log scale for RR and HR.
0.0%, respectively. In contrast, LTFU-definition censoring re-
sulted in substantial downward bias in the risks. Percent bias
in 10-year risk under A = 1 and A = 0 was −11.5% and
−13.3%, respectively. Percent bias in the risk difference,
risk ratio, and hazard ratio was −9.0%, 4.4%, and −0.2%,
respectively. A similar pattern (minor bias under last-encounter
censoring and substantial negative bias under LTFU-definition
censoring) was seen when LTFU was faster among persons
with A = 1. Again, when LTFUwas more likely if Xj = 1, both
censoring schemes produced bias. IPCWs reduced the bias
under last-encounter censoring but were ineffective at removing
bias under LTFU-definition censoring (Web Table 4).
We hypothesized that the minimal upward bias in the risk
estimates for measured outcomes under last-encounter cen-
soring was related to the nonconstant monitoring of indivi-
duals (due to the visit structure). Specifically, when a person
who is LTFU is censored at her last visit, the Kaplan-Meier
estimator begins reallocating that censored person to events
immediately following the last visit. However, if she had been
observed to have the event, due to the nature of the visit struc-
ture, her event would not have been observed until a mean ofM
months later. To explore this theory, we reran the simulation
for random LTFU and random censoring, setting the mean visit
Figure 3. Estimated cumulative incidence (simulation results) of a
captured event Y (event detectable outside a study visit) under A = 1
if persons who are lost to follow-up (LTFU) are censored when they
met the definition of LTFU (LTFU-definition censoring) or at their last
study encounter, compared with truth (absence of LTFU).
Table 2. Bias in the Estimated Effects of a Baseline Exposure on aMeasuredOutcome (e.g., a Biomarker) in the Presence of Loss to Follow-Up
(LTFU)When Person-Time for Those Lost Is Censored at the Time of the Last Encounter or the Point at Which the Definition of LTFU Is Meta
Estimand Truth
Last-Encounter Censoring LTFU-Definition Censoring
Estimate Biasb %Bias Median Bias (IQR) Estimate Biasb %Bias Median Bias (IQR)
LTFU is Random
Risk
A = 1 53.7 55.0 1.3 2.4 0.7 (−1.3 to 3.2) 47.5 −6.2 −11.5 −4.5 (−6.2 to−2.5)
A = 0 32.2 33.3 1.1 3.4 1.2 (−1.3 to 3.6) 27.9 −4.3 −13.3 −6.2 (−8.4 to−4.2)
RD 21.5 21.7 0.2 0.9 0.1 (−3.3 to 3.6) 19.6 −1.9 −9.0 −1.9 (−4.9 to 1.0)
RR 1.67 1.67 −0.007 −1.3 −0.004 (−0.089 to 0.077) 1.72 0.022 4.4 0.020 (−0.057 to 0.103)
HR 1.98 1.98 0.000 0.0 −0.003 (−0.065 to 0.073) 1.98 −0.002 −0.2 −0.005 (−0.068 to 0.072)
LTFUOccurs at a Faster RateWhen A = 1
Risk
A = 1 53.7 55.6 1.9 3.5 0.7 (−1.3 to 2.7) 46.8 −7.0 −13.0 −3.9 (−5.6 to−2.2)
A = 0 32.2 33.1 0.9 2.8 1.5 (−1.3 to 4.7) 28.5 −3.7 −11.6 −7.2 (−9.7 to−4.6)
RD 21.5 22.5 1.0 4.6 0.8 (−2.9 to 4.5) 18.3 −3.3 −15.0 −3.4 (−6.5 to−0.2)
RR 1.67 1.70 0.009 1.7 0.007 (−0.079 to 0.092) 1.66 −0.014 −2.8 −0.015 (−0.100 to 0.066)
HR 1.98 2.02 0.021 3.0 0.022 (−0.047 to 0.087) 1.89 −0.049 −7.1 −0.048 (−0.120 to 0.020)
LTFU is More LikelyWhen Xj = 1
Risk
A = 1 53.7 56.7 3.0 5.5 1.8 (−0.2 to 4.1) 49.8 −3.9 −7.2 −3.1 (−4.6 to−1.2)
A = 0 32.2 34.3 2.1 6.6 2.8 (0.3 to 5.3) 29.4 −2.8 −8.8 −4.0 (−6.0 to−1.9)
RD 21.5 22.4 0.9 4.0 1.0 (−2.4 to 4.1) 20.5 −1.0 −4.8 −1.0 (−3.7 to 1.6)
RR 1.67 1.67 −0.007 −1.4 −0.004 (−0.084 to 0.072) 1.71 0.019 3.8 0.019 (−0.057 to 0.093)
HR 1.98 1.99 0.003 0.5 0.004 (−0.060 to 0.069) 1.98 0.002 0.2 0.002 (−0.060 to 0.069)
Abbreviations: HR, hazard ratio; IQR, interquartile range; LTFU, lost to follow-up; RD, risk difference; RR, risk ratio.
a Full details of the simulations are provided inWeb Appendix 1.
b Absolute bias is on the log scale for RR and HR.
interval to 3 months (M = 3) instead of 6 months. Our theory
would predict that a shorter visit interval should result in small-
er positive bias; and indeed, absolute bias in the risk estimates
for A = 1 and A = 0 was 0.7% and 0.6%, respectively (Web
Table 5), compared with 1.3% and 1.1% when the mean visit
interval was 6 months. The bias in risk estimates (and contrasts
of risk estimates) due to last-encounter censoring for measured
outcomes should be minimal when the risk of the outcome is
low (indeed, we confirmed this by altering parameters in our
simulation; data not shown) or when the visit interval is short;
even in our simulation, in the presence of a high risk and long
visit intervals, bias associated with last-encounter censoringwas
less than the bias associated with LTFU-definition censoring.
We next considered effects of time-varying exposure X and
found similar results. When the outcome was captured, last-
encounter censoring resulted in substantial upward bias of
risk estimates and LTFU-definition censoring was unbiased
(Table 3). When censoring was associated with covariates,
IPCWs minimized bias under LTFU-definition censoring but
did not remove the bias under last-encounter censoring (Web
Table 6). When the outcome was measured, LTFU-definition
censoring produced substantial downward bias of risk estimates,
while last-encounter censoring produced minimal upward
bias of risk estimates (Table 4). IPCWs minimized bias under
last-encounter censoring (but did not eliminate the small positive
bias) but did not remove bias under LTFU-definition censoring
(Web Table 7).
Example
Of 2,446 ART-naive patients enrolled in the Johns Hopkins
HIV Clinical Cohort between January 1, 1998, and August 30,
2015, we excluded 184 (8%) without a baseline CD4 cell count
or viral loadmeasurement. Of the 2,262 patients in the final study
sample, the majority were male (64%) and black (77%). The
median age was 40 years (interquartile range (IQR), 34–47), the
median CD4 cell count was 292 cells/μL (IQR, 120–492), and
the median log10 viral load was 4.3 copies/mL (IQR, 3.2–5.0).
One-third of the sample (34%) reported IDU as their most proba-
ble route of HIV acquisition. Over 5 years of follow-up, 1,541
persons initiated ART and 257 persons died before being LTFU.
Time to ART initiation. Based on simulation results, the
most appropriate censoring scheme when studying ART ini-
tiation would be last-encounter censoring. There were 622
patients LTFU prior to ART initiation, 154 of whom never
returned after their baseline visit. Those 154 persons, plus 19
patients who enrolled less than a year before the end of the study
period (and so never had the opportunity to meet the definition
Table 3. Bias in the Estimated Effects of a Time-Varying Exposure on a CapturedOutcome (e.g., Death) in the Presence of Loss to Follow-Up
(LTFU)When Person-Time for Those Lost Is Censored at the Time of the Last Encounter or the Point at Which the Definition of LTFU Is Meta
Estimand Truth
Last-Encounter Censoring LTFU-Definition Censoring
Estimate Biasb %Bias Median Bias (IQR) Estimate Biasb %Bias Median Bias (IQR)
LTFU is Random
Risk
A = 1 34.3 39.2 4.9 14.3 6.2 (3.7 to 8.8) 34.2 −0.1 −0.3 −0.5 (−2.8 to 2.0)
A = 0 49.8 56.0 6.2 12.5 4.9 (3.0 to 6.8) 49.5 −0.3 −0.6 −0.1 (−1.9 to 1.6)
RD −15.5 −16.9 −1.4 8.7 −1.3 (−4.5 to 1.8) −15.3 0.2 −1.3 0.4 (−2.8 to 3.1)
RR 0.69 0.70 0.015 −4.0 0.016 (−0.054 to 0.080) 0.69 0.003 −0.8 0.008 (−0.069 to 0.074)
HR 0.61 0.60 −0.016 3.2 −0.016 (−0.091 to 0.059) 0.61 −0.001 0.1 0.001 (−0.072 to 0.072)
LTFUOccurs at a Faster RateWhen A = 1
Risk
A = 1 34.3 37.7 3.4 10.1 4.3 (2.0 to 6.7) 32.9 −1.4 −4.0 −2.2 (−4.3 to 0.2)
A = 0 49.8 54.1 4.3 8.7 3.5 (1.5 to 5.3) 47.8 −2.0 −4.1 −1.3 (−3.1 to 0.2)
RD −15.5 −16.4 −0.9 5.8 −0.7 (−3.8 to 2.0) −14.9 0.7 −4.2 0.9 (−2.0 to 3.4)
RR 0.69 0.70 0.012 −3.2 0.017 (−0.051 to 0.077) 0.69 0.000 −0.1 0.007 (−0.070 to 0.071)
HR 0.61 0.60 −0.014 2.9 −0.012 (−0.091 to 0.061) 0.61 0.000 0.0 0.001 (−0.076 to 0.073)
LTFU is More LikelyWhen Xj = 1
Risk
A = 1 34.3 40.2 6.0 17.4 3.8 (1.9 to 5.5) 34.2 0.0 −0.1 −0.2 (−1.9 to 1.6)
A = 0 49.8 53.5 3.7 7.5 6.0 (4.2 to 7.7) 49.6 −0.2 −0.3 0.0 (−1.6 to 1.5)
RD −15.5 −13.3 2.2 −14.3 2.2 (−0.3 to 4.8) −15.4 0.1 −0.8 0.2 (−2.3 to 2.6)
RR 0.69 0.75 0.087 −23.3 0.087 (0.028 to 0.145) 0.69 0.001 −0.3 0.001 (−0.059 to 0.064)
HR 0.61 0.67 0.096 −19.4 0.096 (0.028 to 0.164) 0.61 0.000 −0.1 0.000 (−0.066 to 0.068)
Abbreviations: HR, hazard ratio; IQR, interquartile range; LTFU, lost to follow-up; RD, risk difference; RR, risk ratio.
a Full details of the simulations are provided inWeb Appendix 1.
b Absolute bias is on the log scale for RR and HR.
of LTFU) but did not return for any visits after enrollment, were
completely excluded from the analysis that relied upon last-
encounter censoring.When we used last-encounter censoring,
we estimated that the 5-year covariate-standardized risk of ART
initiation was 85.8 (95% confidence interval (CI): 80.7, 90.1)
among PWID and 90.2 (95% CI: 88.1, 92.3) among non-IDUs
(Table 5). The risk difference and hazard ratio for ART initiation
associated with IDUwere−4.5 (95%CI:−10.1, 0.3) and 0.71
(95% CI: 0.63, 0.79), respectively. When we (inappropriately)
used LTFU-definition censoring, as in the simulation, risks
were biased downward. Risk of ART initiation among PWID
was 78.9 (95% CI: 72.6, 85.1), and that among non-IDUs was
86.5 (95%CI: 83.4, 89.2). The risk difference and hazard ratio
associated with a history of IDU were −7.6 (95% CI: −14.4,
−0.5) and 0.67 (95%CI: 0.59, 0.77), respectively (Table 5).
Time to death. Based on simulation results, themost appro-
enrollment and the end of the study period, were completely
excluded from the analysis that utilized last-encounter censor-
ing. When we used LTFU-definition censoring, we estimated
that the 5-year risk of death was 25.9 (95% CI: 20.9, 31.0)
among PWID and 12.4 (95% CI: 10.2, 15.0) among non-IDUs
(Table 5). IDUwas associated with a risk difference and hazard
ratio for death of 13.4 (95% CI: 8.2, 19.3) and 2.09 (95% CI:
1.61, 2.79), respectively. As in the simulation, when we (inap-
propriately) censored patients who met the definition of LTFU
the last time theywere seen, estimated risks were biased upwards.
Mortality risk was 28.7 (95% CI: 23.0, 34.4) among PWID and
13.2 (95% CI: 11.0, 15.8) among non-IDUs. The risk difference
and hazard ratio associated with a history of IDUwere 15.4 (95%
CI: 9.3, 21.2) and 2.19 (95% CI: 1.64, 2.92), respectively
(Table 5).
Because deaths were captured for all patients in this cohort,
regardless of engagement at the clinic, and because exposure
in this example was ascertained at baseline, we did not actu-
ally have to censor anyone when estimating time to death
associated with IDU; we have only employed various censor-
ing schemes here for the purposes of illustration. The benefit
of this approach in this particular instance is that we can com-
pare results using either censoring scheme with the “true” (no
Table 4. Bias in the Estimated Effects of a Time-Varying Exposure on aMeasuredOutcome (e.g., a Biomarker) in the Presence of Loss to
Follow-Up (LTFU)When Person-Time for Those Lost Is Censored at the Time of the Last Encounter or the Point at Which the Definition of LTFU Is
Meta
Estimand Truth
Last-Encounter Censoring LTFU-Definition Censoring
Estimate Biasb %Bias Median Bias (IQR) Estimate Biasb %Bias Median Bias (IQR)
LTFU is Random
Risk
A = 1 34.0 35.2 1.1 3.4 0.1 (−2.9 to 4.1) 29.7 −4.4 −12.9 −7.2 (−9.9 to−3.7)
A = 0 52.6 53.4 0.9 1.6 1.0 (−1.2 to 3.4) 45.9 −6.7 −12.8 −4.4 (−6.3 to−2.6)
RD −18.5 −18.2 0.3 −1.6 1.0 (−3.9 to 4.7) −16.2 2.3 −12.5 2.9 (−1.2 to 6.0)
RR 0.65 0.67 0.017 −4.0 0.029 (−0.078 to 0.114) 0.65 −0.001 0.2 0.009 (−0.091 to 0.092)
HR 0.56 0.54 −0.027 4.6 −0.023 (−0.100 to 0.051) 0.55 −0.007 1.1 −0.004 (−0.081 to 0.071)
LTFUOccurs at a Faster RateWhen A = 1
Risk
A = 1 34.0 33.5 −0.6 −1.6 −1.8 (−4.9 to 1.5) 28.3 −5.8 −16.9 −8.9 (−11.7 to−5.9)
A = 0 52.6 51.3 −1.3 −2.4 −0.7 (−2.9 to 1.7) 44.0 −8.5 −16.2 −5.8 (−7.6 to−3.9)
RD −18.5 −17.8 0.7 −3.8 1.3 (−2.9 to 5.1) −15.7 2.8 −15.0 3.3 (−0.5 to 6.5)
RR 0.65 0.66 0.009 −2.0 0.014 (−0.084 to 0.104) 0.65 −0.007 1.7 −0.002 (−0.103 to 0.089)
HR 0.56 0.54 −0.024 4.1 −0.021 (−0.105 to 0.054) 0.55 −0.004 0.8 −0.003 (−0.086 to 0.079)
LTFU is More LikelyWhen Xj = 1
Risk
A = 1 34.0 35.2 1.1 3.3 0.2 (−2.3 to 3.1) 28.7 −5.4 −15.7 −4.5 (−6.6 to−1.8)
A = 0 52.6 53.2 0.6 1.2 1.1 (−1.1 to 3.2) 48.4 −4.1 −7.8 −5.3 (−7.1 to−3.8)
RD −18.5 −18.0 0.5 −2.8 0.8 (−3.2 to 4.2) −19.8 −1.3 6.8 −1.2 (−4.3 to 2.0)
RR 0.65 0.67 0.020 −4.6 0.024 (−0.066 to 0.105) 0.60 −0.091 20.9 −0.088 (−0.177 to−0.008)
HR 0.56 0.56 −0.002 0.3 −0.002 (−0.076 to 0.066) 0.50 −0.103 17.5 −0.103 (−0.178 to−0.031)
Abbreviations: HR, hazard ratio; IQR, interquartile range; LTFU, lost to follow-up; RD, risk difference; RR, risk ratio.
a Full details of the simulations are provided inWeb Appendix 1.
b Absolute bias is on the log scale for RR and HR.
priate censoring scheme when studying time to death would be 
LTFU-definition censoring. There were 1,015 patients LTFU 
prior to death, 94 of whom never returned after their baseline 
visit (and did not die within the first year of follow-up). Those 
94 persons, along with 77 patients who enrolled less than a year 
before the administrative censoring date (and so did not meet 
the definition for LTFU) but also did not return or die between
censoring) time to death among PWID and non-IDUs. While
LTFU-definition censoring slightly overestimated 5-year mortal-
ity risk for PWID and non-IDUs, there was substantially less bias
associated with this censoring scheme as compared with last-
encounter censoring. Deviations between the “truth” and LTFU-
definition censored estimatesmay have been due to random error
or to violations of the assumption of uninformative censoring.
DISCUSSION
We have demonstrated here that analytical handling of
person-time in the presence of censoring should depend on
the nature of the study design and the outcome: Persons who are
LTFU when analyzing time to a captured outcome should be
censored when they meet the LTFU definition; persons who are
LTFU when analyzing time to a measured outcome should
be censored at the time when they were last seen. Bias due
to the choice of a censoring scheme that was incompatible with
the outcome under study was not remedied by IPCWs, even
though we assumed that the censoring mechanism was known.
This bias is perhaps most closely conceptually related to immor-
tal time bias (12, 13), as it arises due to excluding person-time
at risk (when using last-encounter censoring for captured out-
comes) or to including person-time not at risk (when using
LTFU-definition censoring formeasured outcomes). The choice
of censoring scheme can have a substantial impact on results, as
was observed in our application, although the magnitude of the
bias will depend upon the risk of the outcome under study and
the risk of LTFU.
Herein, we made several simplifying assumptions about
the underlying processes for the outcome and LTFU in order
to isolate the issue of including versus excluding person-time
between the last visit and the point at which the definition of
LTFU was met. In reality, there are often additional issues
related to analytical handling of censoring that must be con-
sidered. For example, we assumed that censoring was ignor-
able, conditional on covariates (14), and that the censoring
mechanism was known (5). When censoring is not ignorable,
other approaches may be necessary (15–17). This is a com-
monly recognized problem in HIV clinics in resource-limited
settings, where increasing illness severity may reduce the prob-
ability of a patient’s returning for a clinic visit and increase the
mortality hazard, or where failure to return for a clinic visit may
be the direct result ofmortality (16, 18). Furthermore, in our con-
ceptual framework, we assumed that ascertainment of captured
Table 5. Associations (Example, Crude, and Standardized) of History of Injection Drug UseWith Initiation of Antiretroviral Therapy and Death
Among 2,262 Patients Enrolled in the Johns Hopkins HIV Clinical Cohort, Baltimore, Maryland, 1998–2015
Estimand and Censoring Strategy
5-Year Risk
Risk Difference Risk Ratio Hazard Ratio
PWID Non-IDUs
PE 95%CI PE 95%CI PE 95%CI PE 95%CI PE 95%CI
Time from enrollment to ART initiation
Last-encounter censoring
Crude 86.6 82.1, 90.5 90.0 87.6, 92.1 −3.5 −8.1, 0.9 0.96 0.91, 1.01 0.71 0.64, 0.79
Standardizeda 85.8 80.7, 90.1 90.2 88.1, 92.3 −4.5 −10.1, 0.3 0.95 0.89, 1.00 0.71 0.63, 0.79
LTFU-definition censoring
Crude 78.6 73.4, 83.3 85.4 82.7, 88.0 −6.8 −12.1,−1.4 0.92 0.86, 0.98 0.66 0.59, 0.73
Standardizeda 78.9 72.6, 85.1 86.5 83.4, 89.2 −7.6 −14.4,−0.5 0.91 0.84, 0.99 0.67 0.59, 0.77
Time from enrollment to death
Last-encounter censoring
Crude 29.5 25.3, 33.7 12.1 10.2, 14.3 17.4 12.5, 22.3 2.43 1.91, 3.06 2.54 1.98, 3.25
Standardizeda 28.7 23.0, 34.4 13.2 11.0, 15.8 15.4 9.3, 21.2 2.17 1.64, 2.86 2.19 1.64, 2.92
LTFU-definition censoring
Crude 25.3 21.5, 29.3 10.6 8.8, 12.6 14.7 10.4, 19.1 2.39 1.90, 3.01 2.41 1.90, 3.10
Standardizeda 25.9 20.9, 31.0 12.4 10.2, 15.0 13.4 8.2, 19.3 2.08 1.61, 2.75 2.09 1.61, 2.79
Truth (no censoring)
Crude 23.7 20.6, 27.0 11.8 10.2, 13.5 11.9 8.4, 15.7 2.01 1.68, 2.46 2.13 1.75, 2.66
Standardizedb 23.6 20.0, 27.5 12.7 10.9, 14.6 10.9 7.1, 15.2 1.85 1.51, 2.29 1.94 1.55, 2.45
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency
virus; IDU, injection drug use; IDUs, injection drug users; LTFU, lost to follow-up; PE, point estimate; PWID, persons who inject drugs.
a Standardized (with inverse probability of IDU weights) to the distribution of the following covariates in the study sample: male sex, black race,
male-male sex as an HIV acquisition risk factor, and baseline age, prior AIDS diagnosis, prior mono- or dual ART exposure, CD4 cell count, and
log10 viral load; also weighted for possibly differential loss to follow-up associated with the previously listed baseline covariates and time-varying
most recent CD4 cell count, log10 viral load, and AIDS diagnosis.
b Standardized with inverse probability of IDUweights as specified above. Because there was no censoring, no censoring weighting was done.
the outcome of interest and the study design will be largest
when the rate of the event and the rate of LTFU are high. Thus,
this investigation into proper analytical handling of LTFU
is particularly timely and clears up some confusion regarding
the most appropriate censoring time in time-to-event analyses.
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